Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalirudin - The Medicines Company

Next Previous
Drug Profile

Bivalirudin - The Medicines Company

Alternative Names: Angiomax; Angiomax RTU; Angiox; BG-8967; Hirulog-1

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer The Medicines Company
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis; Unstable angina pectoris
  • Discontinued Myocardial infarction

Most Recent Events

  • 24 May 2023 MAIA Pharmaceuticals enters into a distribution agreement with Endo Ventures to distribute bivalirudin injection in ready-to-use vials in USA
  • 15 Dec 2022 3739403: No update
  • 12 May 2022 Updated efficacy data from a phase III BRAVO2/3 trial in Thrombosis prevention presented at the 71st Annual Scientific Session of the American College of Cardiology (ACC-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top